PERJETA (pertuzumab) and Herceptin Prescribing Information for additional Important Safety Information, including most serious side effects.
No clinically meaningful differences were identified between HERZUMA and Herceptin in these studies. These data are not part of the Prescribing Information
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HERCEPTIN safely and effectively. See full prescribing information for HERCEPTIN. HERCEPTIN (trastuzumab) for injection, for intravenous use Initial U.S. Approval: 2024 WARNING: CARDIOMYOPATHY, INFUSION REACTIONS
The Prescribing Information states that Herceptin is shipped in multi-dose vials nominally containing 440 mg Herceptin as a lyophilized
Metastatic Breast Cancer. Metastatic Stomach Cancer. Herceptin (trastuzumab) For US Healthcare Professionals. Uses Important Safety Information for HERCEPTIN and HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) Possible Serious Side Effects With HERCEPTIN.
Prescribing information for Phesgo. [2] US Food and Drug Administration. Prescribing Information for Herceptin. [Internet; cited June 2024]. Prescribing Information for Perjeta [Internet
Prescribing information: Herceptin (trastuzumab). San Francisco, CA prescribing patterns may not follow the information provided in the Formulary.
Please see full Prescribing Information, including Boxed WARNINGS. KANJINTI (trastuzumab-anns) Prescribing Information, Amgen Inc. 2. Herceptin
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information for Herceptin. HERCEPTIN (trastuzumab) Intravenous Infusion Initial U.S. Approval: 2024 . WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY
Comments